These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 22959035)

  • 1. HSP90 inhibitors for cancer therapy and overcoming drug resistance.
    Jhaveri K; Modi S
    Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
    Proia DA; Bates RC
    Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP90 inhibitors: current development and potential in cancer therapy.
    Sidera K; Patsavoudi E
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
    Wang Y; Trepel JB; Neckers LM; Giaccone G
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1466-76. PubMed ID: 21154128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purine-scaffold Hsp90 inhibitors.
    Chiosis G; Tao H
    IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
    De Mattos-Arruda L; Cortes J
    Breast; 2012 Aug; 21(4):604-7. PubMed ID: 22560618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent updates on the development of ganetespib as a Hsp90 inhibitor.
    Choi HK; Lee K
    Arch Pharm Res; 2012 Nov; 35(11):1855-9. PubMed ID: 23212626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
    Solárová Z; Mojžiš J; Solár P
    Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HSP90 as a platform for the assembly of more effective cancer chemotherapy.
    Whitesell L; Lin NU
    Biochim Biophys Acta; 2012 Mar; 1823(3):756-66. PubMed ID: 22222203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
    Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
    Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.
    Jhaveri K; Taldone T; Modi S; Chiosis G
    Biochim Biophys Acta; 2012 Mar; 1823(3):742-55. PubMed ID: 22062686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and application of Hsp90 inhibitors.
    Solit DB; Chiosis G
    Drug Discov Today; 2008 Jan; 13(1-2):38-43. PubMed ID: 18190862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.